KALA BIO (LSE:0JQ2) - Stock Price, News & Analysis

0JQ2 Stock Overview

KALA BIO, Inc. es una empresa biofarmacéutica en fase clínica centrada en el descubrimiento, desarrollo y comercialización de terapias para el tratamiento de enfermedades oculares.

About the company

0JQ2 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Los beneficios han crecido 4.6% al año en los últimos 5 años.

Risk Analysis

Tiene unos ingresos inferiores a 1 millón de dólares ($0)

Cotización muy volátil en los últimos 3 meses

Los accionistas se han diluido en el último año

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

+ 1 more risk

KALA BIO, Inc. Competitors

LungLife AI

AIM:LLAI

UK£9.0m

Oncimmune Holdings

AIM:ONC

UK£15.4m

OptiBiotix Health

AIM:OPTI

UK£18.9m

Verici Dx

AIM:VRCI

UK£19.6m

Price History & Performance

Summary of all time highs, changes and price drops for KALA BIO
Historical stock prices
Current Share Price	US$7.76
52 Week High	US$19.48
52 Week Low	US$5.27
Beta	-1.84
1 Month Change	4.30%
3 Month Change	10.48%
1 Year Change	-47.13%
3 Year Change	-97.97%
5 Year Change	-98.10%
Change since IPO	-98.97%

Recent updates

Shareholder Returns

	0JQ2	GB Biotechs	GB Market
7D	-2.8%	-1.1%	-0.5%
1Y	-47.1%	-29.8%	0.4%

Rentabilidad frente al sector: 0JQ2 obtuvo unos resultados inferiores a los del sector UK Biotechs , que el año pasado arrojó un rendimiento del -32.3%.

Rentabilidad vs. Mercado: 0JQ2 obtuvo unos resultados inferiores a los del mercado UK, que fue del -5.2% el año pasado.

Price Volatility

Is 0JQ2's price volatile compared to industry and market?
0JQ2 volatility
0JQ2 Average Weekly Movement	11.4%
Biotechs Industry Average Movement	7.2%
Market Average Movement	4.9%
10% most volatile stocks in GB Market	11.2%
10% least volatile stocks in GB Market	2.6%

Precio estable de las acciones: 0JQ2 no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: 0JQ2(14%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de los valores de UK.

About the Company

Founded	Employees	CEO	Website
2009	43	Mark Iwicki	https://www.kalarx.com

KALA BIO, Inc. es una empresa biofarmacéutica en fase clínica centrada en el descubrimiento, desarrollo y comercialización de terapias para el tratamiento de enfermedades oculares. Los productos candidatos de la empresa incluyen KPI-012, que está en fase 2b de ensayo clínico para el tratamiento de defectos epiteliales corneales persistentes; EYSUVIS para el tratamiento a corto plazo de los signos y síntomas de la enfermedad del ojo seco; e INVELTYS, un esteroide ocular tópico dos veces al día para el tratamiento de la inflamación y el dolor postoperatorios tras la cirugía ocular. Su producto de desarrollo preclínico, incluido KPI-014 para el tratamiento de enfermedades raras hereditarias de la retina.

KALA BIO, Inc. Fundamentals Summary

How do KALA BIO's earnings and revenue compare to its market cap?
0JQ2 fundamental statistics
Market cap	US$21.41m
Earnings (TTM)	-US$42.20m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.5x

P/E Ratio

Is 0JQ2 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0JQ2 income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$42.20m
Earnings	-US$42.20m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-14.98
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	455.6%

How did 0JQ2 perform over the long term?

See historical performance and comparison

0JQ2 Stock Overview

Rewards

Risk Analysis

KALA BIO, Inc. Competitors

AIM:LLAI

UK£9.0m

AIM:ONC

UK£15.4m

AIM:OPTI

UK£18.9m

AIM:VRCI

UK£19.6m

Price History & Performance

Recent News & Updates

KALA BIO, Inc. announced that it expects to receive $8.599799 million in funding from Baker Bros. Advisors LP

KALA BIO, Inc. announced that it expects to receive $1.999824 million in funding

New major risk - Revenue size

First half 2023 earnings released: US$11.35 loss per share (vs US$41.26 loss in 1H 2022)

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 22, 2023

First quarter 2023 earnings released: US$6.99 loss per share (vs US$22.37 loss in 1Q 2022)

Recent updates

KALA BIO, Inc. announced that it expects to receive $8.599799 million in funding from Baker Bros. Advisors LP

KALA BIO, Inc. announced that it expects to receive $1.999824 million in funding

New major risk - Revenue size

First half 2023 earnings released: US$11.35 loss per share (vs US$41.26 loss in 1H 2022)

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 22, 2023

First quarter 2023 earnings released: US$6.99 loss per share (vs US$22.37 loss in 1Q 2022)

Full year 2022 earnings released: US$29.48 loss per share (vs US$109 loss in FY 2021)

Kala Pharmaceuticals, Inc. announced that it has received $30.999475 million in funding from Baker Bros. Advisors LP

Kala Pharmaceuticals, Inc. Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Kala Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

Kala Pharmaceuticals, Inc. announced that it expects to receive $30.999475 million in funding from Baker Bros. Advisors LP

Kala Pharmaceuticals, Inc. Announces Appointment of Marjan Farid to Its Board of Directors

Insufficient new directors

Second quarter 2022 earnings released: US$0.38 loss per share (vs US$0.56 loss in 2Q 2021)

Kala Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Kala Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Alcon Pharmaceuticals Ltd and Alcon Vision, LLC completed the acquisition of EYSUVIS® and certain assets of Kala Pharmaceuticals, Inc. (NasdaqGS:KALA).

Insufficient new directors

Kala Pharmaceuticals Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Alcon Inc. (SWX:ALC) entered into a agreement to acquire EYSUVIS® and certain assets of Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $385 million.

Alcon Inc. (SWX:ALC) acquired EYSUVIS® from Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $60 million.

First quarter 2022 earnings released: US$0.45 loss per share (vs US$0.49 loss in 1Q 2021)

Kala Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 16, 2022

Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2022

Insufficient new directors

Full year 2021 earnings released: US$2.19 loss per share (vs US$1.99 loss in FY 2020)

Insufficient new directors

Third quarter 2021 earnings released: US$0.43 loss per share (vs US$0.50 loss in 3Q 2020)

No longer forecast to breakeven

Second quarter 2021 earnings released: US$0.56 loss per share (vs US$0.42 loss in 2Q 2020)

Insufficient new directors

Insufficient new directors

First quarter 2021 earnings released: US$0.49 loss per share (vs US$0.54 loss in 1Q 2020)

Kala Pharmaceuticals Announces Preferred Position for Eysuvis™ on Cigna

New 90-day low: US$6.86

Full year 2020 earnings released: US$1.99 loss per share (vs US$2.76 loss in FY 2019)

Revenue misses expectations

Kala Pharmaceuticals, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Kala Pharmaceuticals Announces EYSUVIS™ Now Covered by Express Scripts

Kala Pharmaceuticals, Inc. Announces Availability of EYSUVISTM for the Treatment of Dry Eye Disease and Provides Update on Development Pipeline

Shareholder Returns

Price Volatility

About the Company

KALA BIO, Inc. Fundamentals Summary

0.0x

-0.5x

Earnings & Revenue